Description: Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer.
Home Page: www.panbela.com
PBLA Technical Analysis
712 Vista Boulevard
Waconia,
MN
55387
United States
Phone:
952 479 1196
Officers
| Name | Title |
|---|---|
| Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. | CEO, Pres & Director |
| Ms. Susan Horvath | VP of Fin., CFO, Sec. & Treasurer |
| Ms. Tammy Groene | VP of Operations |
| Dr. Elizabeth Bruckheimer Ph.D. | VP & Chief Scientific Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2198 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-01-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |